Implications for HIV Post-exposure Prophylaxis (PEP)
The United States (US) Centers for Disease Control and Prevention (CDC) released an interim statement on May 23, 2018, regarding the safety of the antiretroviral drug, Dolutegravir (DTG).
Dolutegravir is approved as part of the antiretroviral drug regimen for Post-exposure Prophylaxis (PEP) .
The interim statement gives the following advisory:
Health care providers prescribing PEP should avoid use of DTG for:
• Non-pregnant women of childbearing potential who are sexually active or have been sexually assaulted and who are not using an effective birth control method; and
• Pregnant women early in pregnancy since the risk of an unborn infant developing a neural tube defect is during the first 28 days.
If you are a woman taking PEP, please check whether you are taking Dolutegravir. Contact your Doctor immediately for further advice.